Prevention, detection, and management of early bacterial and fungal infections in a preclinical cardiac xenotransplantation model that achieves prolonged survival

Xenotransplantation

Volumn 12, Issue 2, 2005, Pages 127-133

  Teotia, Sumeet S ^a   Walker, Randall C ^a   Schirmer, Johannes M ^a   Tazelaar, Henry D ^a   Michaels, Marian G ^b   Risdahl, Jack M ^a   Byrne, Guerard W ^a   Logan, John S ^a   McGregor, Christopher G A ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bacterial infections; Cardiac transplantation; Cytomegalovirus; Epstein Barr virus; Fungal infections; Porcine; Porcine endogenous retrovirus infection; Primate; Xenotransplantation

Indexed keywords

CORTICOSTEROID; COTRIMOXAZOLE; GANCICLOVIR; ITRACONAZOLE; RAPAMYCIN; TACROLIMUS; VALACICLOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM DETECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; EXPERIENCE; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; INFECTION PREVENTION; INFECTIOUS COMPLICATION; MODEL; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SWINE; VIRUS INFECTION; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BACTERIAL INFECTIONS; HEART TRANSPLANTATION; HUMANS; MODELS, ANIMAL; MYCOSES; PAPIO; SURVIVAL RATE; SWINE; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; VIRUS DISEASES;

EID: 14644406764     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2005.00205.x     Document Type: Article

References (51)

1. CHAPMAN LE. Xenotransplantation: public health risks-patient vs. society in an emerging field. Curr Top Microbiol Immunol 2003; 278: 23.
2. FISHMAN JA. Infection in xenotransplantation. J Card Surg 2001; 16: 363.
3. BLUSCH JH, PATIENCE C, MARTIN U. Pig endogenous retroviruses and xenotransplantation. Xenotransplantation 2002; 9: 242.
4. MCGREGOR CGA, TEOTIA SS, BYRNE GW et al. Cardiac xenotransplantation: progress towards the clinic. Transplantation 2004; 78: 1569.
5. DIAMOND LE, QUINN CM, MARTIN MJ et al. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation 2001; 71: 132.
6. FISHMAN JA. The risk of infection in xenotransplantation. Ann N y Acad Sci 1998; 862: 45.
7. BORIE DC, CRAMER DV. PHAN-THANH L et al. Microbiological hazards related to xenotransplantation of porcine organs into man. Infect Control Hosp Epidemiol 1998; 19: 355.
8. RISDAHL J, EDGERTON S, ADAMS C, MARTIN M, WISEMAN B. Establishing a designated pathogen free swine colony for xenotransplantation. Proceedings of the 17th Congress of the International Pig Veterinary Society June 2-5, Volume 2, Paper 324, 2002: 149.
9. National Institutes of Health. Guide for the Care and Use of Laboratory Animals. Bethesda: Prepared by the Institute of Laboratory Animal Resources, National Institutes of Health, 1996.
10. ADAMS DH, CHEN RH, KADNER A, NAFICY S. Technique for heterotopic pig heart xenotransplantation in primates. Ann Thorac Surg 1999; 68: 265.
11. ANONYMOUS. U.S. public health service guideline on infectious disease issues in xenotransplantation. MMWR Recomm Rep 2001; 50 (RR-15): 1.
12. ANONYMOUS. Report of the xenotransplantation surveillance workshop: infection control database and sample archiving. Can Commun Dis Rep 2001; 27 (Suppl. 1): 1.
13. BONEVA RS, FOLKS TM, CHAPMAN LE. Infectious disease issues in xenotransplantation. Clin Microbiol Rev 2001; 14: 1.
14. FISHMAN JA. Infection and xenotransplantation: developing strategies to minimize risk. Ann N y Acad Sci 1998; 862: 52.
15. MICHAELS M. Infectious concerns of cross-species transplantation: xenozoonoses. World J Surg 1997; 21: 968.
16. MICHAELS M. Xenozoonoses and the xenotransplant recipient. Ann N y Acad Sci 1998; 862: 100.
17. CHAPMAN L. Xenotransplantation: benefits and risks. Emerg Infect Dis 2001; 7 (Suppl. 3): 545.
18. CHAPMAN L. Xenogeneic infections and public health. Clin Exp Pharmacol Physiol 1999; 26: 1005.
19. RUBIN RH, TOLKOFF-RUBIN NE. The impact of infection on the outcome of transplantation. Transplant Proc 1991; 23: 2068.
20. LAUFER G, LACZKOVICS A, WOLLENEK G et al. Infectious complications in heart transplant recipients with combined low dose cyclosporine, azathioprine, and prednisone (triple drug) immunosuppression. Transplant Proc 1989; 21 (1Pt3): 2508.
21. LOHMANN R, LANGREHR JM, KLUPP J et al. Infectious complications after orthotopic liver transplantation with different immunosuppressive induction regimens. Transplant Proc 2000; 32: 537.
22. LOHMANN R. LANGREHR JM, RAAKOW R et al. Impact of primary immunosuppression on the incidence of infectious complications after orthotopic liver transplantation. Transplant Proc 2000; 32: 2229.
23. LINDER J. Infection as a complication of heart transplantation. J Heart Transplant 1988; 7: 390.
24. BORK J. CHINNOCK R, OGATA K, BAUM M. Infectious complications in infant heart transplantation. J Heart Lung Transplant 1993; 12 (6Pt2): S199.
25. BOUCHUT JC, STAMM D, BOILLOT O, LEPAPE A, FLORET D. Postoperative infectious complications in paediatric liver transplantation: a study of 48 transplants. Paediatr Anaesth 2001; 11: 93.
26. COLONNA JO, WINSTON DJ, BRILL JE et al. Infectious complications in liver transplantation. Arch Surg 1998; 123: 360.
27. COOPER DKC, LANZA RP, OLIVER S et al. Infectious complications after heart transplantation. Thorax 1983; 38: 822.
28. DONNELLY JP. Bacterial complications of transplantation: diagnosis and treatment. J Antimicrob Chemother 1995; 36 (Suppl. B): 59.
29. GROSSI P, MARIA RD, CAROLI A, ZAINA MS, MINOLI L. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. J Heart Lung Transplant 1992; 11: 847.
30. KEATING MR, WILHELM MP. Management of infectious complications following liver transplantation. Curr Clin Top Infect Dis 1993; 13: 226.
31. MERMEL LA, MAKI DG. Bacterial pneumonia in solid organ transplantation. Semin Respir Infect 1990; 5: 10.
32. MONTOYA JG, GIRALDO LF, EFRON B et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33: 629.
33. SINGH N, GAYOWSKI T, WAGENER M, YU VL. Infectious complications in liver transplant recipients on tacrolimus. Transplantation 1994; 58: 774.
34. SINGH N. The current management of infectious diseases in the liver transplant recipient. Clin Liver Dis 2000; 4: 657.
35. VASKA PL. Common infections in heart transplant patients. Am J Crit Care 1993; 2: 145.
36. WINSTOND J, EMMANOUILIDES C, BUSUTTIL RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21: 1077.
37. BLOCK KC, NADARAJA R, JACOBS R. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Medicine (Baltimore) 1997; 76: 30.
38. MUELLER JM, SULLING K, GOLLACKNER B et al. Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation. Am J Transplant 2003; 3: 1057.
39. RUBIN RH. Prevention of cytomegalovirus infection in organ transplant recipients. Transplant Infect Dis 2000; 2: 99.
40. GORENSEK MJ, STEWART RW, KEYS TF et al. Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. J Infect Dis 1988; 158: 884.
41. RAND KH, POLLARD RB, MERIGAN TC. Increased pulmonary superinfections in cardiac transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978; 298: 951.
42. FARMER DG, MCDIARMID SV, WINSTON D et al. Effectiveness of aggressive prophylactic and preemptive therapies targeted against cytomegaloviral and Epstein-Barr viral disease after human intestinal transplantation. Transplant Proc 2002; 34: 948.
43. KEAY S, OLDACH D, WILAND A et al. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 1998; 26: 596.
44. MCDIARMID SV, STAN J, LEE GS et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.
45. DARENKOV IA, MARCARELLI MA, BASADONNA GP et al. Reduced incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848.
46. GREEN M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103.
47. AMPEL NM, WING EJ. Legionella infection in transplant patients. Semin Respir Infect 1990; 5: 65.
48. CHAPMAN SW, WILSON JP. Nocardiosis in transplant recipients. Semin Respir Infect 1990; 5: 74.
49. SINNOTT JT, EMMANUEL PJ. Mycobacterial infections in the transplant patient. Semin Respir Infect 1990: 5: 65.
50. GREENE PS, CAMERON DE, AUGUSTINE S et al. Exploratory analysis of time-dependent risk for infection, rejection, and death after cardiac transplantation. Ann Thorac Surg 1989; 47: 650.
51. ONIONS D, COOPER DKC, ALEXANDER TJL et al. An approach to the control of disease transmission in pig-to-human xenotransplantation. Xenotransplantation 2000; 7: 143.